{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:12:29Z","timestamp":1769854349696,"version":"3.49.0"},"reference-count":48,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R017867\/1"],"award-info":[{"award-number":["MR\/R017867\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R025096\/1"],"award-info":[{"award-number":["MR\/R025096\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S009426\/1"],"award-info":[{"award-number":["MR\/S009426\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2024,2,27]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Novel therapeutic strategies are urgently needed for<jats:italic>Mycobacterium avium<\/jats:italic>complex pulmonary disease (MAC-PD). Human mesenchymal stromal cells (MSCs) can directly inhibit MAC growth, but their effect on intracellular bacilli is unknown. We investigated the ability of human MSCs to reduce bacterial replication and inflammation in MAC-infected macrophages and in a murine model of MAC-PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Human monocyte-derived macrophages (MDMs) were infected with<jats:italic>M. avium<\/jats:italic>Chester strain and treated with human bone marrow-derived MSCs. Intracellular and extracellular colony-forming units (CFUs) were counted at 72 hours. Six-week-old female balb\/c mice were infected by nebulisation of<jats:italic>M. avium<\/jats:italic>Chester. Mice were treated with 1\u00d710<jats:sup>6<\/jats:sup>intravenous human MSCs or saline control at 21 and 28 days post-infection. Lungs, liver and spleen were harvested 42 days post-infection for bacterial counts. Cytokines were quantified by ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MSCs reduced intracellular bacteria in MDMs over 72 hours (median 35% reduction, p=0.027). MSC treatment increased extracellular concentrations of prostaglandin E2 (PGE2) (median 10.1-fold rise, p=0.002) and reduced tumour necrosis factor-\u03b1 (median 28% reduction, p=0.025). Blocking MSC PGE2 production by cyclo-oxygenase-2 (COX-2) inhibition with celecoxib abrogated the antimicrobial effect, while this was restored by adding exogenous PGE2. MSC-treated mice had lower pulmonary CFUs (median 18% reduction, p=0.012), but no significant change in spleen or liver CFUs compared with controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MSCs can modulate inflammation and reduce intracellular<jats:italic>M. avium<\/jats:italic>growth in human macrophages via COX-2\/PGE2 signalling and inhibit pulmonary bacterial replication in a murine model of chronic MAC-PD.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thorax-2023-220819","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T17:20:42Z","timestamp":1710955242000},"page":"778-787","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Human mesenchymal stromal cells inhibit<i>Mycobacterium avium<\/i>replication in clinically relevant models of lung infection"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-5391","authenticated-orcid":false,"given":"Timothy D","family":"Shaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-5069","authenticated-orcid":false,"given":"Anna D","family":"Krasnodembskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar N","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Declan F","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnatas Dutra","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikha M","family":"Tandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca J","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia M","family":"O'Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"2025042101250791000_79.8.778.1","doi-asserted-by":"crossref","first-page":"106164","DOI":"10.1016\/j.rmed.2020.106164","article-title":"Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation","volume":"173","author":"Schildkraut","year":"2020","journal-title":"Respir Med"},{"key":"2025042101250791000_79.8.778.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00149212"},{"key":"2025042101250791000_79.8.778.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"2025042101250791000_79.8.778.4","doi-asserted-by":"publisher","DOI":"10.1038\/nature09262"},{"key":"2025042101250791000_79.8.778.5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13287-015-0271-2","article-title":"Biodistribution, migration and homing of systemically applied mesenchymal stem\/stromal cells","volume":"7","author":"Leibacher","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"2025042101250791000_79.8.778.6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00339"},{"key":"2025042101250791000_79.8.778.7","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2369"},{"key":"2025042101250791000_79.8.778.8","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2372"},{"key":"2025042101250791000_79.8.778.9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01228","article-title":"The necrobiology of mesenchymal stromal cells affects therapeutic efficacy","volume":"10","author":"Weiss","year":"2019","journal-title":"Front Immunol"},{"key":"2025042101250791000_79.8.778.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-218194"},{"key":"2025042101250791000_79.8.778.11","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1183\/13993003.02021-2017","article-title":"Mesenchymal stem cells enhance NOX2-dependent reactive oxygen species production and bacterial killing in macrophages during sepsis","volume":"51","author":"Rabani","year":"2018","journal-title":"Eur Respir J"},{"key":"2025042101250791000_79.8.778.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.07.001"},{"key":"2025042101250791000_79.8.778.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074997"},{"key":"2025042101250791000_79.8.778.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.03874.x"},{"key":"2025042101250791000_79.8.778.15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S2213-2600(13)70234-0","article-title":"Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial","volume":"2","author":"Skrahin","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025042101250791000_79.8.778.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-020-01324-2","article-title":"A phase IB\/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded CX611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit","volume":"20","author":"Laterre","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2025042101250791000_79.8.778.17","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210672"},{"key":"2025042101250791000_79.8.778.18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcf.2022.12.001","article-title":"A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis","volume":"22","author":"Roesch","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025042101250791000_79.8.778.19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/sctm.20-0521","article-title":"Donor-defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium","volume":"10","author":"Bonfield","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"2025042101250791000_79.8.778.20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.6.3767"},{"key":"2025042101250791000_79.8.778.21","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(74)90109-4"},{"key":"2025042101250791000_79.8.778.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200810-1584OC"},{"key":"2025042101250791000_79.8.778.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001307","article-title":"Human macrophage responses to clinical isolates from the mycobacterium tuberculosis complex discriminate between ancient and modern lineages","volume":"7","author":"Portevin","year":"2011","journal-title":"PLoS Pathog"},{"key":"2025042101250791000_79.8.778.24","first-page":"e00834","article-title":"A new Tractable method for generating human alveolar macrophage-like cells in vitro to study lung inflammatory processes and diseases","volume":"14","author":"Susanta","year":"2023","journal-title":"mBio"},{"key":"2025042101250791000_79.8.778.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201701-0170OC"},{"key":"2025042101250791000_79.8.778.26","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00064-21","article-title":"Mesenchymal stromal cells: an antimicrobial and host-directed therapy for complex infectious diseases","volume":"34","author":"Shaw","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"2025042101250791000_79.8.778.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.12.008"},{"key":"2025042101250791000_79.8.778.28","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200106049"},{"key":"2025042101250791000_79.8.778.29","first-page":"2419","article-title":"Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase","volume":"54","author":"Powis","year":"1994","journal-title":"Cancer Res"},{"key":"2025042101250791000_79.8.778.30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.310"},{"key":"2025042101250791000_79.8.778.31","doi-asserted-by":"publisher","DOI":"10.1002\/stem.544"},{"key":"2025042101250791000_79.8.778.32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04841-14"},{"key":"2025042101250791000_79.8.778.33","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.626216","article-title":"A Clofazimine-containing regimen confers improved treatment outcomes in macrophages and in a murine model of chronic progressive pulmonary infection caused by the mycobacterium avium complex","volume":"11","author":"Lee","year":"2020","journal-title":"Front Microbiol"},{"key":"2025042101250791000_79.8.778.34","doi-asserted-by":"crossref","DOI":"10.3390\/ph16020220","article-title":"Human mesenchymal stem cell (hMSC) donor potency selection for the \u201cfirst in cystic fibrosis\u201d phase I clinical trial (CEASE-CF)","volume":"16","author":"Bonfield","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025042101250791000_79.8.778.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126994","article-title":"Pathogenic nontuberculous mycobacteria resist and inactivate cathelicidin: implication of a novel role for polar mycobacterial lipids","volume":"10","author":"Honda","year":"2015","journal-title":"PLoS ONE"},{"key":"2025042101250791000_79.8.778.36","doi-asserted-by":"crossref","DOI":"10.1093\/nargab\/lqz010","article-title":"Global variability analysis of mRNA and protein concentrations across and within human tissues","volume":"2","author":"Wegler","year":"2020","journal-title":"NAR Genom Bioinform"},{"key":"2025042101250791000_79.8.778.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-38982-0","article-title":"Mycobacterium tuberculosis Rv3463 induces mycobactericidal activity in macrophages by enhancing phagolysosomal fusion and exhibits therapeutic potential","volume":"9","author":"Park","year":"2019","journal-title":"Sci Rep"},{"key":"2025042101250791000_79.8.778.38","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis609"},{"key":"2025042101250791000_79.8.778.39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.meegid.2016.10.016","article-title":"Polymorphisms in the prostaglandin receptor EP2 gene confers susceptibility to tuberculosis","volume":"46","author":"Liang","year":"2016","journal-title":"Infect Genet Evol"},{"key":"2025042101250791000_79.8.778.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-016-1938-8","article-title":"The COX- inhibitor indomethacin reduces Th1 Effector and T regulatory cells in vitro in mycobacterium tuberculosis infection","volume":"16","author":"Tonby","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2025042101250791000_79.8.778.41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/sctm.17-0209","article-title":"Concise review: quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem\/stromal cells","volume":"7","author":"Brooks","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"2025042101250791000_79.8.778.42","doi-asserted-by":"crossref","first-page":"695278","DOI":"10.3389\/fimmu.2021.695278","article-title":"Mesenchymal stem cells and tuberculosis: clinical challenges and opportunities","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2025042101250791000_79.8.778.43","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2353"},{"key":"2025042101250791000_79.8.778.44","doi-asserted-by":"crossref","DOI":"10.1038\/ni0202-102a","article-title":"Species differences in macrophage NO production are important","volume":"3","author":"Schneemann","year":"2002","journal-title":"Nat Immunol"},{"key":"2025042101250791000_79.8.778.45","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/s41598-017-15290-z","article-title":"Mesenchymal stem cells internalize mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy","volume":"7","author":"Khan","year":"2017","journal-title":"Sci Rep"},{"key":"2025042101250791000_79.8.778.46","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16877-3","article-title":"Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to mycobacterium tuberculosis","volume":"11","author":"Jain","year":"2020","journal-title":"Nat Commun"},{"key":"2025042101250791000_79.8.778.47","doi-asserted-by":"crossref","first-page":"38308","DOI":"10.1038\/srep38308","article-title":"Human mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE 2 -dependent mechanism","volume":"6","author":"Vasandan","year":"2016","journal-title":"Sci Rep"},{"key":"2025042101250791000_79.8.778.48","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.3892\/mmr.2016.5694","article-title":"Comparison of bone marrow tissue- and adipose tissue-derived mesenchymal stem cells in the treatment of sepsis in a murine model of lipopolysaccharide-induced sepsis","volume":"14","author":"Ou","year":"2016","journal-title":"Mol Med Rep"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-220819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:26:02Z","timestamp":1745223962000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-220819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,7,16]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/thorax-2023-220819"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-220819","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}